Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(0)
# 3954
Out of 5,218 analysts
25
Total ratings
40.91%
Success rate
-2.44%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
argenx | Maintains: Outperform | 675 706 | 606.64 | 16.38% | 4 | Nov 21, 2024 | |
Sarepta Therapeutics | Maintains: Outperform | 179 170 | 123.57 | 37.57% | 9 | Nov 7, 2024 | |
Jasper Therapeutics | Maintains: Outperform | 65 65 | 20.51 | 216.92% | 2 | Aug 26, 2024 | |
Foghorn Therapeutics | Initiates Coverage On: Outperform | 20 | 5.32 | 275.94% | 1 | Aug 19, 2024 | |
Krystal Biotech | Maintains: Outperform | 201 206 | 163.31 | 26.14% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 25 15 | 2.8 | 435.71% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 62 66 | 42.34 | 55.88% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 22 | 3.23 | 581.11% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 20 10 | 4.38 | 128.31% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 159 165 | 173.5 | -4.9% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 54 60 | 14.61 | 310.68% | 1 | Oct 5, 2022 |